BridgeBio has significantly improved this progress of the new treatment for cardiac amyloidosis, leveraging the investigational drug. Early trial data suggests potential outcomes for individuals affected from a severe https://bridgebio814189.dailyblogzz.com/42617306/company-progresses-cardiac-amyloidosis-management-with-attruby